Connect with us

Biotech

Spanish government approves $57.1 million for the supply of radiopharmaceuticals in the SAS

The pharmacist specializing in nuclear medicine will have to ensure the supply of radiopharmaceuticals to the centers dependent on the Andalusian Health Service (SAS) over the next 48 months. According to the terms stated in a contract, Curium Pharma will be responsible for safely sending materials to hospitals as well as taking responsibility for waste disposal.

Published

on

This picture show a medicine being put on a bottle.

Curium Pharma has been awarded a macro contract in Andalusia, Spain. The pharmaceutical company has been awarded a $57,1 million (€52.3 million) contract to supply radiopharmaceuticals to the Andalusian Health Service (SAS) centers over the next 48 months. The company will also be responsible for the maintenance of the equipment dedicated to nuclear medicine treatments and the management of the waste generated.

The regional executive justified the contract by stating that “the SAS must have radiopharmaceuticals in conditions to be administered to patients who need them.” The Andalusian government points out that “radiopharmaceuticals have the legal status of special medicines and the facilities where they are handled are subject to very strict legislation on nuclear safety; their application can only be carried out in the nuclear medicine services or units of hospitals.”

Breaking news from the biotech, clinical research, and pharmaceutical industries. Born2Invest mobile app is the home of the life sciences industry. Read the latest biotechnology articles on biotech industry leaders, emerging biotech companies, financial headlines, and other biotech industry news.

Curium Pharma, a major player in medicine

Curium Pharma was born from the merger of two world giants in nuclear medicine: the American IBA Molecular and the Irish Mallinckrodt. The European company, named after scientists Marie and Pierre Curie, treats fourteen million patients a year in more than sixty countries. It has a portfolio of more than 6,000 clients and employs 2,000 qualified professionals.

Drawing on over 100 years of experience, Curium combines proven heritage with a pioneering approach to deliver innovation, excellence and unparalleled service. Known as the world’s leading provider of nuclear medicine, Curium has a single focus – to develop, manufacture and supply world-class radiopharmaceutical products to customers around the globe.

SEE ALSO  Why stock buybacks are such a mistake

Similarly, Curium has a portfolio of 50 products that are produced in three manufacturing plants and distributed through 44 nuclear pharmacies in the U.S. and Europe. The company’s headquarters are located in London, Paris, St. Louis (USA) and Luxembourg. In Spain, its headquarters are located in Alcobendas, Madrid. The company has been awarded the contract to supply radiopharmaceuticals to other administrations in addition to Andalusia. In Madrid, the company is responsible for supplying this type of medication to the Gregorio Maranon University Hospitals.

Curium made the news in February 2019 because the National Commission of Markets and Competition (CNMC) opened a sanctioning procedure against the company for possible restrictive practices in the production and commercialization of radiopharmaceuticals. The commission accused Curium Pharma of making a pact with Advanced Accelerator Applications Ibérica to share the market, set prices and exchange information.

Radiopharmaceuticals, an unstable medication

Radiopharmaceuticals have a number of characteristics that make them different from other conventional drugs. This type of product emits radioactivity and undergoes radioactive degradation, so its composition varies relatively quickly and has a very short effective half-life.

These characteristics require special management of the waste they generate. “From the preparation to the administration to the patient, waste materials, containers, equipment or instruments contaminated with radiation are produced, which is biohazardous and must be treated scrupulously so as not to cause accidental damage,” stated the Andalusian Government in the tender report.

For this reason, the contract requires that the company that won the tender, which in this case is Curium, is also responsible for the waste disposal function. Similarly, it must be responsible for sending the material to hospitals safely.

SEE ALSO  Essential format components to include in your newsletter

__

(Featured image by Kelly Sikkema via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantDoce., a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.

Eva Wesley is an experienced journalist, market trader, and financial executive. Driven by excellence and a passion to connect with people, she takes pride in writing think pieces that help people decide what to do with their investments. A blockchain enthusiast, she also engages in cryptocurrency trading. Her latest travels have also opened her eyes to other exciting markets, such as aerospace, cannabis, healthcare, and telcos.